RxDoctor Payments Data

Thomas Byrnes

Family · Wilmington, DENPI 1700509296

Payments from drug & device makers

$2,436in general payments, 2019–2025

Across 129 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$606
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$461
  • Valinor Pharma, LLC$336
  • Scilex Pharmaceuticals Inc.$234
  • Vertos Medical, Inc.$207
  • Nevro Corp.$138
  • plus $454 from 11 others

What the payments were for

  • Food & beverage$2,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,436 in reported general payments places this provider in the 80th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$4,109
Medicare patients
15
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate137$90,457
BelbucaBuprenorphine Hcl73$57,626
OxycontinOxycodone Hcl63$42,718
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,232$36,840
MovantikNaloxegol Oxalate81$32,916
ZtlidoLidocaine52$21,976
Nucynta ErTapentadol Hcl14$15,654
Oxycodone Hcl726$13,458
Tramadol Hcl ErTramadol Hcl222$12,070
Lidocaine152$10,957
Gabapentin584$7,509
Buprenorphine35$6,494
Pregabalin369$5,410
Fentanyl32$4,778
Cyclobenzaprine Hcl277$3,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$606$163,737224 claims
Scilex Pharmaceuticals Inc.Ztlido$234$21,97652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →